Insulet Corporation (NASDAQ: PODD) — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a separate fourth-quarter report; the supplied filing text does not provide a clear Q4-only financial summary.
Business context
Insulet develops, manufactures and sells the Omnipod tubeless insulin-delivery system. It also supplies customized drug-delivery devices, primarily for Amgen’s Neulasta Onpro kit. Omnipod sales generated $1.01 billion of FY2021 revenue; drug delivery generated $87.4 million. Approximately 300,000 people globally used Omnipod, and 76% of Omnipod sales were through intermediaries.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $1,098.8 million | $904.4 million |
| Gross profit / gross margin | $752.1 million / 68.4% | $582.3 million / 64.4% |
| Operating income / margin | $126.0 million / 11.5% | $51.5 million / 5.7% |
| Net income | $16.8 million | $6.8 million |
| Diluted earnings per share | $0.24 | $0.10 |
| Cash from operating activities | $(68.1) million | $84.0 million |
| Capital expenditures | $111.9 million | $129.0 million |
Revenue increased 21.5% year over year (19.7% at constant currency), primarily on higher Omnipod volumes. U.S. Omnipod revenue rose 23.6%; international Omnipod rose 16.9% reported and 11.6% at constant currency; drug-delivery revenue rose 25.8%. Gross-margin improvement reflected better manufacturing efficiency, pharmacy-channel mix and lower pandemic-related costs.
Operating cash flow turned negative, mainly due to a $263.6 million working-capital outflow, including inventory growth of $154.4 million and higher receivables of $71.3 million. Cash and cash equivalents were $791.6 million at year-end, down from $907.2 million. The company said current liquidity should cover projected operating, investing and debt-service needs for at least 12 months. FY2021 cash, cash equivalents and restricted cash at year-end totaled $806.4 million.
Debt totaled $1.4 billion in principal obligations at year-end, including $800 million of 0.375% convertible notes due 2026 and a $500 million term loan due 2028; the balance-sheet carrying amount of total debt, net, was $1,273.9 million. No amount was drawn on the $60 million revolving credit facility. The company repurchased and converted its 1.375% notes in 2021, recognizing a $42.4 million extinguishment loss.
Material changes, outlook and commentary
- Gross margin increased 400 basis points, while operating income more than doubled. Net income remained modest, in part reflecting interest expense and the debt-extinguishment loss.
- Management expected strong 2022 Omnipod growth, led by DASH and the U.S. pharmacy channel; international growth was expected from DASH adoption, with competition and pandemic effects as offsets. Drug-delivery revenue was expected to decline as pandemic-elevated production normalized.
- Management projected 2022 gross margin of 67%–68%, citing product mix, Omnipod 5 costs, U.S. manufacturing scale-up, inflation and supply-chain disruption; efficiencies and pharmacy-channel growth were expected to help offset these pressures. R&D and SG&A spending were expected to increase.
- Omnipod 5 received FDA clearance in January 2022 for people aged six and older with type 1 diabetes; a limited U.S. market release began in February 2022. These were post-year-end developments. The company had submitted for European CE marking and pursued expanded indications.
- In January 2022, Insulet paid $29 million to acquire a supplier and made a $5 million strategic investment. It also planned further manufacturing investment and international expansion.
Risks, contingencies and unusual items
- Business and revenue are highly reliant on Omnipod; key risks include competition, reimbursement and coverage, customer retention, regulatory approvals, product quality, manufacturing scale-up and reliance on suppliers, including China-based production and sole-source components.
- COVID-19 and global supply-chain disruption could affect customer starts, production, labor availability, costs and regulatory timelines. Currency movements are also relevant: approximately 33% of revenue was denominated in foreign currencies.
- Roche patent litigation in the U.S. sought monetary damages and fees. The patent had expired, so Roche was not seeking an injunction; Insulet said it could not estimate potential losses, which could be material. A U.S. trial was scheduled for July 2022.
- Customer and channel concentration warrant attention: two distributors each represented at least 10% of revenue, and two distributors together accounted for 35% of trade receivables at year-end. FY2021 included $58.2 million of revenue from a distributor related to a board member’s spouse; the company said the agreement was on arm’s-length terms.
- Grant Thornton issued unqualified opinions on the financial statements and internal control over financial reporting. The filing identified the debt repurchase and conversion accounting as a critical audit matter.
Important facts for investors to verify
- Whether Omnipod 5 converts its clearance and limited release into adoption, revenue growth and sustainable margins.
- Whether working-capital investment—particularly inventory and receivables—reverses into positive operating cash flow.
- Actual 2022 gross margin, manufacturing costs, capital spending and the pace of U.S. and international capacity expansion.
- Debt-service obligations, term-loan covenants, convertible-note dilution exposure and the effect of the January 2022 convertible-debt accounting change.
- Developments and potential financial exposure in the Roche litigation, and the durability of reimbursement, supplier arrangements and major customer relationships.